Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead Sciences’ CEO ...
Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease (TED) through a phase 3 trial and hopefully on to commercialization. | Sling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results